The 6 Areas of Excellence

75 ultimate
 TRADING shortcuts
this is just a handful of what's inside:

Spot Volatility Opportunity in 30 Seconds

The Secret to Understanding ETFs

Shortcut to The Bull Call Spread

Retirees Secret Weapon: Self Directed IRA

7 Fun Facts About Futures Trading

Beat the Street - Earnings Hack

Cut Out the Noise - Avoiding Indicator Overload

How to Construct a Basic Risk Reversal

The Mystery of the Backspread Unveiled

Demystifying Time Decay

Rising Trading Stars You Need to Follow

Set Investing Goals In Less Than 5 Minutes

9 Trading Quotes You Should Write Down

4 Steps You Need to Make Better Trades

A No-Brainer Guide to Fundamentals

The Key To Better Trading Revealed

Shortcut to Trading the Open

Understand Earnings Reports to Maximize Profits

Exactly When To Take Profit

How TV Financial “Experts” Are Killing Your Trades

2 Ways to Protect Your Portfolio with Options

3D Investing – Divide, Diversify and Use Different Accounts

BIOTECH SPOTLIGHT:

CNS Pharmaceuticals | NASDAQ: CNSP

This corporate profile is a paid advertisement and is provided for information purposes only; it should not be used as the basis for any investment decision. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the SEC) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained in this corporate profile is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them. This corporate profile has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in this corporate profile. Individuals should assume that all information in this corporate profile is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.  As of December 7th, 2019, Trade Stocks and Strikepoint Media have received total compensation of three hundred and sixty-one thousand dollars from CNS Pharmaceuticals for the preparation, publication, and management of this corporate profile as well as other marketing and investor relations services. We anticipate receiving additional compensation up to the amount of five hundred thousand dollars for the duration of the campaign.  Trade Stocks, Strikepoint Media, and its principals currently hold no shares in CNS Pharmaceuticals, but may buy or sell such shares at any time without notice. This compensation and position constitute a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.

Information contained in this corporate profile will contain “forward-looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Readers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.

Statistical information, dollar amounts, and market size data was provided by the profiled company and related sources which we believe to be reliable. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided herein, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC and the Financial Industry Regulatory Authority (“FINRA”).

©2020 Trade Stocks. All Rights Reserved.   

RISK DISCLAIMER: Before deciding to participate in any investment, you should carefully consider your investment objectives, level of experience and risk tolerance. Most importantly, do not invest money you cannot afford to lose. Trade Stocks is not a registered broker-dealer. Trade Stocks does not give investment advice, endorsement, analysis or recommendations with respect to any securities. Trade Stocks has not taken any steps to verify the adequacy, accuracy or completeness of any information. Neither Trade Stocks nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Trade Stocks does not make investment recommendations and no communication, through this website or in any other medium should be construed as an investment recommendation. Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. Additionally, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.

 Positive FDA Pre-IND Guidance Received! 
Brain Cancer Drug Candidate: Berubicin

From the Desk of John Climaco, CEO of CNS Pharmaceuticals:

One Company 
with Patented Potential to Revolutionize the  ^$4.8 Billion Tattoo Removal Industry

One Company 
with Patented Potential to Revolutionize the  ^$4.8 Billion Tattoo Removal Industry

Being diagnosed with any type of cancer is a life-changing event for you and your entire family, but if you’re one of the unlucky individuals to get diagnosed with glioblastoma, the most aggressive type of brain cancer, then, unfortunately, it gets much tougher.

Glioblastoma is the type of brain cancer that led to the death of Senator Ted Kennedy, Vice President Joe Biden’s son and Senator John McCain.

Our lead drug candidate called Berubicin, which received positive FDA Pre-IND guidance, was developed at the M.D. Anderson Cancer Center in Houston, the largest cancer treatment and research institute in the world, appears to have crossed the blood-brain barrier and kill brain tumor cells not reachable by other therapies.

Hi, I’m John Climaco and I’m the CEO of CNS Pharmaceuticals, a NASDAQ listed company trading under the ticker symbol CNSP, and I’m here to introduce you to our company because I believe it merits the attention of all smallcap investors because of our leading brain cancer drug candidate.

In other words, Berubicin may become an effective treatment against glioblastoma, the most aggressive type of brain cancer.

From the Desk of John Climaco, CEO of CNS Pharmaceuticals:

Berubicin is part of a category of drugs called anthracyclines, and the reason we consider Berubicin to be an important new drug technology is because Berubicin is one of the first anthracyclines that appear to cross the blood-brain barrier and actually kill brain tumor cells in cancer patients.

Now it’s important to understand that there is currently no proven cure for glioblastoma. This means that even with the best care in the world, the average patient survives only 14 to 16 months after diagnosis.  Sadly, this means that a glioblastoma diagnosis is essentially a death sentence, as we unfortunately just saw with Senator John McCain. The good news is that Berubicin has the potential to change the way we treat patients suffering from this aggressive and deadly disease.

Continued... From the Desk of John Climaco, CEO of CNS Pharmaceuticals:

As I mentioned earlier, anthracyclines are a class of drugs… what I didn't tell you is that they are considered by most oncologists to be the most effective anticancer treatments ever developed and they are effective against more types of cancer than any other class of chemotherapeutic agents for cancers like breast, ovarian, leukemia, lymphoma, testicular and others.

Anthracyclines are also generally effective in killing glioblastoma cancer cells as well, but historically they only worked in the test tube. The reason for this is simple… the blood-brain barrier has stopped all anthracyclines from getting all the way to the brain, except possibly for Berubicin…..

Berubicin is one of the first anthracyclines that does not appear to require a specific carrier to be able to cross over the blood-brain barrier and get into the brain. None of the drugs that require carriers have been shown to be effective in humans.

How does it work? 

I'll show you, but first, let's look at what happens when other anthracyclines attempt to cross the blood-brain barrier.

When a conventional anthracycline is given to patients intravenously, the drug molecules travel to the heart and are then pumped throughout the body and toward the brain, but the blood-brain barrier was beautifully designed to protect the brain from foreign substances that could harm the brain like anthracyclines and other chemotherapy agents. 

So it quickly recognizes these poisons and kicks them out. 

The blood-brain barrier is a protective wall of specialized endothelial cells that separate the blood from the brain tissue.

Special structures called efflux pumps in the cells make up the blood-brain barrier and recognize anthracyclines and kick them back out into the blood before they can even get into the brain.

They act like bouncers at a nightclub... when they see the anthracyclines they grab it and throw it out preventing it from reaching the tumor. That's why anthracyclines have historically killed glioblastoma cells in test tubes, but don't affect glioblastoma tumors when given to people. 

Now let's see why we believe Berubicin may work. 

Berubicin is given intravenously so it also gets to the brain through the circulatory system and it appears that it is not stopped by the blood-brain barrier. Berubicin was engineered specifically to be invisible to the efflux pumps in the blood-brain barrier. That's why we believe Berubicin, unlike other anthracyclines, appears to get across the blood-brain barrier and inside the brain to fight tumor cells. 

Once it gets inside the glioblastoma cells, Berubicin has been formulated to kill them which has been shown to result in an overall shrinkage of the tumor.

It is important to keep in mind that the above is based on limited clinical data on Berubicin and we will need to undertake additional clinical trials on Berubucin.

We believe Berubicin may prove to be a new discovery that has the potential to save lives. In fact, we have a collaboration and asset purchase agreement with Reata Pharmaceuticals, an approximately six and a half billion dollars publicly-traded company, related to the development of Berubicin.

So if you’re looking for promising cancer technologies, then we believe CNS Pharmaceuticals has a very unique opportunity for investors in the biotech space.

If you would like to follow the progress of Berubicin, then sign up on our website and fill out your contact info.

We look forward to having you join us on this amazing journey to fight this terrible disease and many more!

CEO of CNS Pharmaceuticals